| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
44 |
| Employees |
34 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-57 |
| Cash Flow (TTM) (Millions $) |
-198 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Theseus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, USA. It specializes in developing innovative immunotherapy treatments for cancer patients. Founded in 2016, the company is led by an experienced management team, including Dr. John C. Reed, MD, PhD, as the CEO and Dr. Frank Nestle, MD, PhD, as the Chief Scientific Officer.
Theseus Pharmaceuticalse pipeline focuses on immune cell therapies that target solid tumors. Its lead product candidate, ThNK-1, is a CAR-T (Chimeric Antigen Receptor T-cell) therapy that targets the protein CD73, which is highly expressed in various cancer cells. ThNK-1 is in Phase 1 clinical trials for the treatment of advanced solid tumors.
The company also has several other preclinical programs in development, including TNK-2, a dual-targeting CAR-T therapy for the treatment of solid tumors, and TNK-3, a TCR (T-cell receptor) therapy for targeting solid tumors with neoantigens.
Theseus Pharmaceuticals has received significant funding from reputable sources. It has raised more than $120 million in various rounds of financing from investors, including Canaan Partners, 6 Dimensions Capital, Morningside Ventures, and Parian Global Management.
The company collaborates with prominent research institutions and biopharmaceutical companies to advance its technologies. Theseus has strategic partnerships with the University of British Columbia and Novartis for the development and commercialization of its CAR-T and TCR therapies.
Overall, Theseus Pharmaceuticals is a promising biotechnology company that aims to improve cancer treatment options through innovative immunotherapies. Its strong management team, well-funded pipeline, and strategic partnerships are likely to continue to drive its growth in the coming years.
Company Address: 314 Main Street Cambridge 2142 MA
Company Phone Number: 400-9491 Stock Exchange / Ticker: NASDAQ THRX
|
%
6.85%